Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.
Industry, Sector and Symbol
Sub-IndustryLife Sciences Tools & Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity12.64%
Return on Assets8.17%
Covance (NYSE:CVD) Frequently Asked Questions
What is Covance's stock symbol?
Covance trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVD."
How were Covance's earnings last quarter?
Covance Inc. (NYSE:CVD) issued its earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share for the quarter, hitting the consensus estimate of $0.97. The healthcare company earned $634 million during the quarter, compared to the consensus estimate of $631.30 million. Covance had a net margin of 7.70% and a return on equity of 12.64%. View Covance's Earnings History.
Has Covance been receiving favorable news coverage?
Headlines about CVD stock have been trending positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Covance earned a coverage optimism score of 0.46 on Accern's scale. They also gave media coverage about the healthcare company an impact score of 45.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Covance?
Shares of CVD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covance's stock price today?
One share of CVD stock can currently be purchased for approximately $107.07.
How big of a company is Covance?
Covance has a market capitalization of $6.06 billion.
How can I contact Covance?
Covance's mailing address is 210 Carnegie Ctr, PRINCETON, NJ 08540-6233, United States. The healthcare company can be reached via phone at +1-609-4524440.
MarketBeat Community Rating for Covance (CVD)MarketBeat's community ratings are surveys of what our community members think about Covance and other stocks. Vote "Outperform" if you believe CVD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Covance (NYSE:CVD) Analyst Ratings History
(Data available from 4/26/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Covance (NYSE:CVD) Earnings History and Estimates Chart
Covance (NYSE CVD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/4/2015||Q414||$0.97||$0.97||$631.30 million||$634.00 million||View||N/A|
|11/3/2014||Q314||$0.98||$0.98||$651.00 million||$627.00 million||View||N/A|
|7/29/2014||Q214||$0.93||$0.95||$639.80 million||$687.10 million||View||N/A|
|5/1/2014||Q114||$0.90||$0.90||$632.01 million||$620.10 million||View||N/A|
|2/4/2014||Q413||$0.84||$0.87||$613.80 million||$623.00 million||View||N/A|
|10/29/2013||Q3 2013||$0.80||$0.83||$595.55 million||$647.05 million||View||N/A|
|7/30/2013||Q2 2013||$0.77||$0.78||$586.12 million||$644.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.72||$0.75||$569.34 million||$580.20 million||View||N/A|
|1/24/2013||Q4 2012||$0.71||$0.73||$548.84 million||$562.20 million||View||N/A|
|11/5/2012||Q312||$0.67||$0.72||$546.52 million||$597.66 million||View||N/A|
Covance (NYSE:CVD) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Covance (NYSE CVD) Insider Trading and Institutional Ownership History
Covance (NYSE CVD) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/22/2014||Brian H Nutt||Insider||Sell||1,127||$103.51||$116,655.77|| |
|12/18/2014||Joseph L Herring||CEO||Sell||32,692||$103.02||$3,367,929.84|| |
|12/10/2014||John E Watson||VP||Sell||15,200||$102.94||$1,564,688.00|| |
|9/9/2014||Joseph L Herring||CEO||Sell||32,200||$85.13||$2,741,186.00|| |
|2/20/2014||James Lovett||VP||Sell||14,955||$102.47||$1,532,438.85||45,981|| |
|2/10/2014||Brian Nutt||Insider||Sell||1,808||$100.12||$181,016.96||1,099|| |
|2/10/2014||Richard Cimino||EVP||Sell||13,000||$99.10||$1,288,300.00||55,462|| |
|2/10/2014||Sandra Helton||Director||Sell||2,800||$99.03||$277,284.00||15,688|| |
|9/20/2013||Richard Cimino||EVP||Sell||16,000||$84.86||$1,357,760.00||59,437|| |
|9/5/2013||Sandra L Helton||Director||Sell||3,000||$81.92||$245,760.00|| |
|9/5/2013||William E Klitgaard||VP||Sell||25,323||$81.44||$2,062,305.12|| |
|8/21/2013||Deborah Keller||EVP||Sell||15,900||$83.12||$1,321,608.00||53,029|| |
|8/16/2013||Robert Barchi||Director||Sell||13,667||$82.78||$1,131,354.26||4,740|| |
|8/2/2013||Gary Costley||Director||Sell||7,467||$82.77||$618,043.59||4,540|| |
|8/2/2013||Joseph Herring||CEO||Sell||100,000||$82.54||$8,254,000.00||229,704|| |
|6/27/2013||Joseph L Herring||CEO||Sell||13,259||$77.00||$1,020,943.00|| |
|6/19/2013||Joseph L Herring||CEO||Sell||22,391||$78.03||$1,747,169.73|| |
|5/15/2013||James W Lovett||VP||Sell||10,259||$77.00||$789,943.00|| |
Covance (NYSE CVD) News Headlines
Covance (NYSE:CVD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Covance (NYSE:CVD) Income Statement, Balance Sheet and Cash Flow Statement
Covance (NYSE CVD) Stock Chart for Thursday, April, 26, 2018